Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Advances in Endometrial Cancer Therapy: Exploring the Role of Immunotherapy

Ana Oaknin, MD, PhD
Released: December 22, 2020
Back Next


  1. Zhang S, Gong TT, Liu FH, et al. Global, regional, and national burden of endometrial cancer, 1990–2017: results from the Global Burden of Disease Study, 2017. Front Oncol. 2019;9:1440.
  2. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
  3. Torre LA, Islami F, Siegel RL, et al. Global cancer in women: burden and trends. Cancer Epidemiol Biomarkers Prev. 2017;26:444-457.
  4. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer stat facts: uterine cancer. Available at: https://seer.cancer.gov/statfacts/html/corp.html. Accessed November 23, 2020.
  5. Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913-2921.
  6. Mittica G, Ghisoni E, Giannone G, et al. Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. Oncotarget. 2017;8:90532-90544.
  7. Felix AS, Weissfeld JL, Stone RA, et al. Factors associated with type I and type II endometrial cancer. Cancer Causes Control. 2010;21:1851-1856.
  8. Dedes KJ, Wetterskog D, Ashworth A, et al. Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol. 2011;8:261-271.
  9. Cancer Genome Atlas Research Network, Kandoth C, Schulz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67.
  10. Luchini C, Bibeau F, Ligtenberg MJL, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019;30:1232-1243.
  11. Cortes-Ciriano I, Lee S, Park WY, et al. A molecular portrait of microsatellite instability across multiple cancers. Nat Commun. 2017;8:15180.
  12. Howitt BE, Shukla SA, Sholl LM, et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 2015;1:1319-1323.
  13. Green AK, Feinberg J, Makker V, et al. A review of immune checkpoint blockade therapy in endometrial cancer. Am Soc Clin Oncol Educ Book. 2020;40:1-7.
  14. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509-2520.
  15. Ott PA, Bang YJ, Berton-Rigaud D, et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1–positive endometrial cancer: results from the KEYNOTE-028 study. J Clin Oncol. 2017;35:2535-2541.
  16. US Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication. Accessed December 14, 2020.
  17. Pembrolizumab [package insert]. North Wales, PA: Merck Sharp & Dohme Corp; 2020.
  18. ClinicalTrials.gov. Study of pembrolizumab (MK-3475) in participants with advanced solid tumors (MK-3475-158/KEYNOTE-158). Available at: https://clinicaltrials.gov/ct2/show/NCT02628067. Accessed December 14, 2020.
  19. O’Malley D, Marabelle A, De Jesus-Acosta A, et al. Pembrolizumab in patients with MSI-H advanced endometrial cancer from the KEYNOTE-158 study. Program and abstracts of the 2019 European Society for Medical Oncology Congress; September 27 - October 1, 2019; Barcelona, Spain. Abstract 3394.
  20. Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38:1-10.
  21. Oaknin A, Gilbert L, Tinker AV, et al. Safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): results from GARNET. Program and abstracts of the 2020 European Society for Medical Oncology Virtual Congress; September 19-21, 2020. Abstract LBA36.
  22. Konstantinopoulos PA, Luo W, Liu JF, et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. J Clin Oncol. 2019;37:2786-2794.
  23. Antill YC, Kok PS, Robledo K, et al. Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601). Program and abstracts of the 2019 American Society of Clinical Oncology annual meeting; May 31 - June 4, 2019; Chicago, Illinois. Abstract 5501.
  24. US Food and Drug Administration. Simultaneous review decisions for pembrolizumab plus lenvatinib in Australia, Canada and US. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/simultaneous-review-decisions-pembrolizumab-plus-lenvatinib-australia-canada-and-us. Accessed December 14, 2020.
  25. Makker V, Taylor MH, Aghajanian C, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol. 2020;38:2981-2992.
  26. ClinicalTrials.gov. Lenvatinib in combination with pembrolizumab versus treatment of physician's choice in participants with advanced endometrial cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]). Available at: https://clinicaltrials.gov/ct2/show/NCT03517449. Accessed December 14, 2020.
  27. Makker V, Herraez AC, Aghajanian C, et al. A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial cancer. Program and abstracts of the 2019 American Society of Clinical Oncology annual meeting; May 31 - June 4, 2019; Chicago, Illinois. Abstract TPS5607.
  28. ClinicalTrials.gov. Pembrolizumab (MK-3475) plus lenvatinib (E7080/MK-7902) versus chemotherapy for endometrial carcinoma (ENGOT-en9 / MK-7902-001) (LEAP-001). Available at: https://clinicaltrials.gov/ct2/show/NCT03884101?term=NCT03884101&draw=2&rank=1. Accessed December 14, 2020.
  29. Marth C, Vulsteke C, Pérez CJR, et al. ENGOT-en9/LEAP-001: A phase III study of first-line pembrolizumab plus lenvatinib versus chemotherapy in advanced or recurrent endometrial cancer. Program and abstracts of the 2020 American Society of Clinical Oncology Virtual Scientific Meeting; May 29-31, 2020. Abstract TPS6106.
  30. Lheureux S, Matei D, Konstantinopoulos PA, et al. A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer. Program and abstracts of the 2020 American Society of Clinical Oncology Virtual Scientific Meeting; May 29-31, 2020. Abstract 6010.
  31. ClinicalTrials.gov. Testing the addition of the immunotherapy drug pembrolizumab to the usual chemotherapy treatment (paclitaxel and carboplatin) in stage III-IV or recurrent endometrial cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT03914612. Accessed December 14, 2020.
  32. ClinicalTrials.gov. Atezolizumab Trial in Endometrial Cancer - AtTEnd (AtTEnd). Available at: https://clinicaltrials.gov/ct2/show/NCT03603184. Accessed December 14, 2020.
  33. ClinicalTrials.gov. A study to evaluate dostarlimab plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel in participants with recurrent or primary advanced endometrial cancer (RUBY). Available at: https://clinicaltrials.gov/ct2/show/NCT03981796. Accessed December 14, 2020.
Back Next

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings